CHINA

EL GIGANTE CHINO ELIGE LA VACUNA ISRAELÍ  CONTRA LA HEPATITIS C.

Actualmente China cuenta con 43 millones de personas que sufren el mal causado por la Hepatis C. Ahora China adquiere la vacuna israelí para proteger a su país contra este tipo de hepatitis.
Los laboratorios hebreos han firmado un ventajoso acuerdo con la Farmacéutica China Jiangsu Chia-tai Tianquing  para el desarrollo y venta del producto israelí, contra la hepatitis C, llamado BL-8030 , por vía oral.


¡Muy mal día para
los antisemitas nazis
particarios del boicot
a Israel!
  Esther la "sorcière".
  Le Groupe

BL-8030

	Indication:	Hepatitis C (HCV)
	Mode of Action:	A second generation HCV NS3/4A inhibitor
	Stage of development:	Pre-clinical
	Patent Status:	International patent application pending, 20 years expiration in 2030

BL-8030 OverviewBL-8030 is a very potent and selective HCV NS3/4A inhibitor which has demonstrated a high genetic barrier to development of resistant variants.  BL-8030 has favorable in vitrocharacteristics including potency, selectivity, activity against resistant mutants, reduced P450 enzyme inhibition and a wide therapeutic index.
Pre-Clinical DataBL-8030 demonstrated excellent potency in the low nanomolar range against the wild type HCV NS3/4A protein.
BL-8030 has demonstrated a higher genetic barrier to resistance than other NS3/4A protease inhibitors. The fold resistance was low (<10 a156s="" a156t="" against="" and="" br="" clinically="" fold="" major="" mutations="" relevant="" resistance="" t54a="">BL-8030 demonstrated  several thousand-fold selectivity relative to a panel of human proteases and did not inhibit cytochrome P450.

BL-8030 was invented by Prof. Philippe Halfon (Genoscience) and Prof. Raymond Schinazi (RFS Pharma).

BL-8030 is being developed by BioLineRx, Ltd. under a worldwide exclusive license